Eduardo Samaniego, MD
Family Medicine · Newark, NJNPI 1699930123
Payments from drug & device makers
Across 549 payments — averaging $22.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- Novo Nordisk$2K
- Boehringer Ingelheim$2K
- Lilly USA, LLC$1K
- AstraZeneca$1K
- Sanofi-aventis U.S. LLC$549
- plus $4K from 33 others
What the payments were for
- Food & beverage$12,17197%
- Education$3183%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 67 | $2,288 |
| Novo Nordisk | 110 | $1,806 |
| Boehringer Ingelheim | 44 | $1,619 |
| Lilly USA, LLC | 76 | $1,496 |
| AstraZeneca | 57 | $1,174 |
| Sanofi-aventis U.S. LLC | 25 | $549 |
| Dexcom, Inc. | 13 | $449 |
| Merck | 30 | $411 |
| Abbott | 6 | $337 |
| Amgen(2 entities) | 11 | $268 |
| AbbVie(2 entities) | 19 | $262 |
| Corcept Therapeutics | 9 | $234 |
| Biotronik Inc. | 2 | $226 |
| Redhill Biopharma Inc. | 12 | $162 |
| Pfizer | 9 | $143 |
| Ardelyx, Inc. | 6 | $140 |
| Bard Peripheral Vascular, Inc. | 1 | $135 |
| Gilead | 7 | $98 |
| Amarin Pharma, Inc. | 7 | $88 |
| Dynavax Technologies Corporation | 7 | $87 |
| Exact Sciences | 3 | $70 |
| Bayer | 3 | $62 |
| Althera Pharmaceuticals LLC | 4 | $54 |
| VBI Vaccine (delaware) Inc. | 3 | $44 |
| Scilex Pharmaceuticals Inc. | 3 | $41 |
| Hologic Sales And Service, LLC | 1 | $33 |
| Eisai Inc. | 2 | $27 |
| Edwards Lifesciences | 1 | $25 |
| Viiv Healthcare Company | 1 | $17 |
| Renalytix AI, Inc. | 1 | $17 |
| Phadia US Inc. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Johnson & Johnson | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Nestle Healthcare Nutrition Inc. | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Xeris Pharmaceuticals, Inc. | 1 | $13 |
| Novartis | 1 | $13 |
| Mannkind Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$1,300
- TRELEGY ELLIPTA$606
- AREXVY$374
- SOLIQUA 100/33$229
- DEXCOM G6 TRANSMITTER$226
- RYBELSUS$220
- LUTONIX$135
- Repatha$125
- BREZTRI$125
- AIRSUPRA$124
- FREESTYLE LIBRE 3$119
- Solia$106
- Rivacor$106
- Acticor$106
- Edora$106
- BioMonitor$106
- FARXIGA$106
How this compares
$12,489 in reported general payments places this provider in the 95th percentile of 2,084 family medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tresiba Flextouch U-200Insulin Degludec | 83 | $88,518 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 79 | $81,516 |
| MounjaroTirzepatide | 40 | $58,015 |
| JanumetSitagliptin Phos/Metformin Hcl | 57 | $57,528 |
| JardianceEmpagliflozin | 40 | $56,438 |
| FarxigaDapagliflozin Propanediol | 54 | $54,778 |
| TradjentaLinagliptin | 50 | $52,688 |
| TrulicityDulaglutide | 33 | $52,449 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 63 | $52,245 |
| Tresiba Flextouch U-100Insulin Degludec | 71 | $50,333 |
| JanuviaSitagliptin Phosphate | 37 | $49,589 |
| OzempicSemaglutide | 36 | $41,958 |
| LinzessLinaclotide | 24 | $25,078 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $23,935 |
| Abilify MaintenaAripiprazole | 11 | $21,703 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanumet Xr, Janumet, Januvia | $411 | $188,633173 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,496 | $110,46373 claims |
| Boehringer IngelheimJardiance, Tradjenta | $1,619 | $109,12690 claims |
| GSKTrelegy Ellipta, Shingrix, Breo Ellipta, Arexvy | $2,288 | $71,059130 claims |
| AstraZenecaFarxiga | $1,174 | $54,77854 claims |
| Novo NordiskOzempic | $1,806 | $41,95836 claims |
| AbbVieLinzess | $262 | $25,07824 claims |
| PfizerEliquis | $143 | $19,79017 claims |
| NovartisEntresto | $13 | $9,85913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,084 family medicine providers in New Jersey.
Other family medicine in Newark
- Howard HassmanClementon$47.1M
- Matthew HongNorth Cape May$15.3M
- Rubaba HussainClark$3.8M
- Gaurang BrahmbhattHoboken$2.6M
- Michael DobrowClifton$2.1M
- Mikhail VarshavskiChatham$1.4M
- Amit BhalodiaCamden$707K
- Jennifer AmicoNew Brunswick$627K
- Janet ColeFar Hills$466K
- Matthew PintoMarlton$239K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.